Sign in
Taking people in NetherlandsPhase 1

Tests tucatinib and osimertinib in brain tumors and cancer spread to the brain

Tests tucatinib and osimertinib in adults with brain tumors or cancer spread to the brain.

Key facts

Who runs it
Amsterdam UMC Stichting
Where
Amsterdam, NetherlandsSee the site
Registry title
Study Investigating Tucatinib and Osimertinib Pharmacokinetics in Primary and Metastatic Brain Tumors: the STICK trial
Status
Recruiting
Phase
Phase 1
People taking part
20 people, planned
Started
26 May 2026
Expected to end
1 Oct 2027
Type of study
Interventional
Record updated
25 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with breast cancer, non-small cell lung cancer or glioblastoma (a brain tumour). It studies how the drugs tucatinib and osimertinib behave in brain tumours.

Age
18 years or older
Sex
Women and men can join.
Disease stage
The record names breast cancer, non-small cell lung carcinoma and glioblastoma; no stage is given.

Main reasons for not taking part

  • Healthy volunteers cannot join.

Where in Netherlands

  • Amsterdam UMC StichtingAmsterdam, NetherlandsTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests tucatinib and osimertinib in brain tumors and cancer spread to the brainGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
25 February 2026